{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:49:19Z","timestamp":1791312559196,"version":"4.3.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jpba.2016.04.039","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T07:29:02Z","timestamp":1462001342000},"page":"75-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Development and validation of a rapid and sensitive UPLC\u2013MS\/MS method for determination of uracil and dihydrouracil in human plasma"],"prefix":"10.1016","volume":"126","author":[{"given":"Bart A.W.","family":"Jacobs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Meulendijks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Henricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2016.04.039_bib0005","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpba.2016.04.039_bib0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/FPC.0b013e328348c6f2","article-title":"PharmGKB summary: fluoropyrimidine pathways","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.jpba.2016.04.039_bib0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1006263400888","article-title":"A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug","volume":"17","author":"Judson","year":"1999","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.jpba.2016.04.039_bib0020","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2016.04.039_bib0025","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1517\/14740338.2010.511610","article-title":"Safety of capecitabine: a review","volume":"9","author":"Mikhail","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jpba.2016.04.039_bib0030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.4155\/bio.14.304","article-title":"Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells","volume":"7","author":"Pluim","year":"2015","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2016.04.039_bib0035","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s00216-012-6614-2","article-title":"Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination","volume":"405","author":"Pluim","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2016.04.039_bib0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/clinchem\/46.1.9","article-title":"Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency","volume":"46","author":"van Kuilenburg","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jpba.2016.04.039_bib0045","first-page":"2899","article-title":"Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients","volume":"52","author":"Fleming","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpba.2016.04.039_bib0050","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.10599","article-title":"Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1G>A mutation","volume":"101","author":"van Kuilenburg","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jpba.2016.04.039_bib0055","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bjc.6690098","article-title":"Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity","volume":"79","author":"Milano","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jpba.2016.04.039_bib0060","first-page":"4705","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene","volume":"6","author":"Van Kuilenburg","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2016.04.039_bib0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/bmc.2741","article-title":"LC-MS\/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients","volume":"27","author":"B\u00fcchel","year":"2013","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2016.04.039_bib0070","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1570-0232(02)00009-0","article-title":"Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry","volume":"769","author":"Jiang","year":"2002","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2016.04.039_bib0075","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00280-011-1661-5","article-title":"Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency","volume":"68","author":"van Staveren","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2016.04.039_bib0080","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jchromb.2006.02.046","article-title":"High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil\/uracil ratio in plasma","volume":"834","author":"D\u00e9porte","year":"2006","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2016.04.039_bib0085","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1373\/clinchem.2007.102251","article-title":"HPLC with UV or mass spectrometric detection for quantifying endogenous uracil and dihydrouracil in human plasma","volume":"54","author":"Svobaite","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jpba.2016.04.039_bib0090","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1177\/147323001003800413","article-title":"The value of dihydrouracil\/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients","volume":"38","author":"Kristensen","year":"2010","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.jpba.2016.04.039_bib0095","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/chromsci\/bms085","article-title":"Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5 6-dihydrouracil in human plasma","volume":"50","author":"Coudor\u00e9","year":"2012","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2016.04.039_bib0100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1570-0232(02)00239-8","article-title":"Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity","volume":"774","author":"Garg","year":"2002","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2016.04.039_bib0105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jchromb.2005.05.044","article-title":"An accurate dihydrouracil\/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice","volume":"823","author":"Remaud","year":"2005","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2016.04.039_bib0110","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2710.2004.00569.x","article-title":"A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity","volume":"29","author":"Ciccolini","year":"2004","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.jpba.2016.04.039_bib0115","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1080\/10826079708000481","article-title":"A simple chromatographic method for the analysis of pyrimidines and their dihydrogenated metabolites","volume":"20","author":"Gamelin","year":"1997","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.jpba.2016.04.039_bib0120","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.clinbiochem.2015.04.019","article-title":"Improved determination of uracil and dihydrouracil in plasma after a loading oral dose of uracil using high-performance liquid chromatography with photodiode array detection and porous graphitic carbon stationary phase","volume":"48","author":"Hahn","year":"2015","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jpba.2016.04.039_bib0125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/FTD.0b013e318240405f","article-title":"A rapid HPLC-ESI-MS\/MS method for determination of dihydrouracil\/uracil ratio in plasma: evaluation of toxicity to 5-flurouracil in patients with gastrointestinal cancer","volume":"34","author":"C\u00e9sar","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2016.04.039_bib0130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jchromb.2006.02.016","article-title":"Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes","volume":"839","author":"Sparidans","year":"2006","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2016.04.039_bib0135","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/clinchem\/46.12.1916","article-title":"Defects in pyrimidine degradation identified by HPLC-electrospray tandem mass spectrometry of urine specimens or urine-soaked filter paper strips","volume":"46","author":"van Lenthe","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jpba.2016.04.039_bib0140","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1373\/clinchem.2005.058842","article-title":"Comprehensive detection of disorders of purine and pyrimidine metabolism by HPLC with electrospray ionization tandem mass spectrometry","volume":"52","author":"Hartmann","year":"2006","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jpba.2016.04.039_bib0145","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-4939-3182-8_25","article-title":"Urine Pyrimidine Metabolite Determination by HPLC Tandem Mass Spectrometry","volume":"1378","author":"Sun","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jpba.2016.04.039_bib0150","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s10545-005-0133-7","article-title":"Comprehensive analysis of pyrimidine metabolism in 450 children with unspecific neurological symptoms using high-pressure liquid chromatography-electrospray ionization tandem mass spectrometry","volume":"28","author":"Schmidt","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.jpba.2016.04.039_bib0155","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1570-0232(03)00251-4","article-title":"Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas chromatography-tandem mass spectrometry","volume":"791","author":"Hofmann","year":"2003","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2016.04.039_bib0160","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00280-014-2553-2","article-title":"Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy","volume":"74","author":"Carlsson","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2016.04.039_bib0165","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/147323001003800212","article-title":"Correlation between thymidylate synthase gene variants, RNA and protein levels in primary colorectal adenocarcinomas","volume":"38","author":"Kristensen","year":"2010","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.jpba.2016.04.039_bib0170","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage","volume":"17","author":"Gamelin","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2016.04.039_bib0175","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1177\/0091270004268911","article-title":"Important role of the dihydrouracil\/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics","volume":"44","author":"Jiang","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2016.04.039_bib0180","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2217\/pgs.14.126","article-title":"Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio","volume":"15","author":"Sistonen","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jpba.2016.04.039_bib0185","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000099984","article-title":"The dihydrouracil\/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients","volume":"53","author":"Zhou","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jpba.2016.04.039_bib0190","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","article-title":"5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency","volume":"249","author":"Boisdron-Celle","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jpba.2016.04.039_bib0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00007691-200502000-00006","article-title":"A simple and sensitive fully validated HPLC-UV method for the determination of 5-fluorouracil and its metabolite 5,6-dihydrofluorouracil in plasma","volume":"27","author":"Maring","year":"2005","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2016.04.039_bib0200","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf, 2011 (accessed 22.11.2015)."},{"key":"10.1016\/j.jpba.2016.04.039_bib0205","unstructured":"US Food and Drug Administration, Department of Health and Human Services, http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070107.pdf, 2001 (accessed 22.11.2015)."},{"key":"10.1016\/j.jpba.2016.04.039_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00928361","article-title":"Physiological concentrations of purines and pyrimidines","volume":"140","author":"Traut","year":"1994","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.jpba.2016.04.039_bib0215","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.biocel.2006.04.007","article-title":"The role of thymidine phosphorylase and uridine phosphorylase in (fluoro)pyrimidine metabolism in peripheral blood mononuclear cells","volume":"38","author":"Temmink","year":"2006","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jpba.2016.04.039_bib0220","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/sj.bjc.6690097","article-title":"Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients","volume":"79","author":"Van Kuilenburg","year":"1999","journal-title":"Br. J. Cancer."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516302254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516302254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T04:32:13Z","timestamp":1600489933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708516302254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":44,"alternative-id":["S0731708516302254"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2016.04.039","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a rapid and sensitive UPLC\u2013MS\/MS method for determination of uracil and dihydrouracil in human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2016.04.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}